1 No-Brainer Biotech Stock To Buy Today and Never Sell

Company Overview - Regeneron is a well-established biotech company with over 35 years of experience, generating billions in revenue through various products, including treatments for inflammation, cholesterol, and eye diseases [4]. Key Products - The company is notably recognized for Dupixent, a blockbuster drug developed in partnership with Sanofi, which treats eight inflammation-related conditions, including asthma and atopic dermatitis, with over one million patients using it globally [5]. - Eylea, another significant product, treats wet age-related macular degeneration and other retinal diseases. The lower dose version has faced competition, but the higher dose version, Eylea HD, saw a 66% increase in U.S. revenue, exceeding $500 million in the recent quarter, indicating its role as a growth driver [6]. Pipeline and Future Growth - Regeneron boasts a substantial pipeline with numerous late-stage programs across various therapeutic areas, including immunology, inflammation, cardiovascular, oncology, and rare diseases, with more than a dozen candidates in phase 3 trials [7]. - The extensive pipeline suggests that even if only a fraction of these candidates reach commercialization, Regeneron is poised for significant growth in the coming years, with new product launches expected to offset declines from older drugs [8].